Daiichi Sankyo Showcases Advances in Cancer Care at ASCO

Daiichi Sankyo is set to unveil significant advancements in oncology at the upcoming 2024 American Society of Clinical Oncology (ASCO) Scientific Program. Highlighting the event will be over 45 abstracts, showcasing the company's strides in cancer treatment.

One of the key presentations will be on the late-breaking results from the phase 3 DESTINY-Breast06 trial, which evaluates the efficacy of ENHERTU® (trastuzumab deruxtecan) against standard chemotherapy for patients with HR-positive, HER2 low, or HER2 ultralow metastatic breast cancer who have undergone one or more lines of endocrine therapy. These findings will be discussed in an ASCO press briefing, underscoring how ENHERTU is challenging traditional classifications and treatments of breast cancer. Ken Takeshita, MD, Global Head of R&D at Daiichi Sankyo, emphasized that these results build on the transformative outcomes seen in the previous DESTINY-Breast04 trial, further cementing ENHERTU’s role in treating certain metastatic breast cancer patients.

Also noteworthy are updated survival results from the DESTINY-Breast03 phase 3 trial, comparing ENHERTU with trastuzumab emtansine (T-DM1) in patients with previously treated HER2 positive metastatic breast cancer. Interim results from the phase 1b/2 DESTINY-Breast07 trial, evaluating ENHERTU both as a monotherapy and in combination with pertuzumab in untreated HER2 positive metastatic breast cancer patients, will also be presented.

The breadth of ENHERTU research extends beyond breast cancer. Final results from the DESTINY-Lung02 phase 2 trial in patients with previously treated HER2 mutant non-small cell lung cancer (NSCLC) will be showcased, alongside sub-analyses from the DESTINY-PanTumor02 phase 2 trial. This trial explores ENHERTU's efficacy in HER2 expressing metastatic biliary tract and pancreatic cancers, bladder cancer, and head and neck cancer. The data from DESTINY-PanTumor02 contributed to the recent accelerated U.S. approval of ENHERTU for a tumor-agnostic indication in unresectable or metastatic HER2 positive solid tumors.

Daiichi Sankyo’s portfolio at ASCO will also feature additional data on datopotamab deruxtecan (Dato-DXd). This includes sub-analyses from the TROPION-Lung02 phase 1b trial, which evaluates Dato-DXd in combination with pembrolizumab and platinum chemotherapy as a first-line treatment for advanced or metastatic NSCLC. Furthermore, the intracranial efficacy of datopotamab deruxtecan in patients with actionable genomic alterations in advanced NSCLC will be discussed, alongside patient-reported outcomes from the TROPION-Breast01 phase 3 trial comparing Dato-DXd with chemotherapy in hormone receptor-positive, HER2 negative metastatic breast cancer patients.

The ASCO presentations will also include trials-in-progress for other investigational drugs such as ifinatamab deruxtecan (I-DXd) in relapsed small cell lung cancer and raludotatug deruxtecan (R-DXd) in platinum-resistant ovarian cancer. Additionally, the HERTHENA-PanTumor01 phase 2 trial will evaluate patritumab deruxtecan (HER3-DXd) in metastatic solid tumors, while the first-in-human phase 1/2 trial of DS-3939 will target advanced solid tumors.

Combinations of Daiichi Sankyo’s DXd ADCs (antibody-drug conjugates) with a novel medicine in development will be explored. This includes a phase 1b trial evaluating valemetostat, an EZH1/EZH2 inhibitor, in combination with ENHERTU or datopotamab deruxtecan in solid tumor patients, and another phase 1b trial assessing valemetostat with ENHERTU in HER2 low, ultralow, and null metastatic breast cancers.

Daiichi Sankyo’s presence at ASCO underscores their commitment to advancing cancer treatment through innovative research and development, aiming to set new standards of care for patients worldwide.